Trade

with

The Medicines Company
(NASDAQ: MDCO)
AdChoices
21.90
-0.09
-0.39%
After Hours :
-
-
-

Open

21.75

Previous Close

21.99

Volume (Avg)

251.24k (664.77k)

Day's Range

21.63-22.38

52Wk Range

19.92-41.28

Market Cap.

1.43B

Dividend Rate ( Yield )

-

Beta

1.05

Shares Outstanding

65.13M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 687.86M

    • Net Income

    • 15.51M

    • Market Cap.

    • 1.43B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -0.16

    • PEG (Price/Earnings Growth) Ratio

    • 1.17

    • Beta

    • 1.05

    • Forward P/E

    • 12.02

    • Price/Sales

    • 1.99

    • Price/Book Value

    • 1.57

    • Price/Cash flow

    • 10.29

      • EBITDA

      • 64.39M

      • Return on Capital %

      • -0.08

      • Return on Equity %

      • -0.15

      • Return on Assets %

      • -0.08

      • Book Value/Share

      • 13.98

      • Shares Outstanding

      • 65.13M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 50.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • 0.24

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 6.30

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -69.70

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 14.59

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 59.09

            • 64.72

            • Pre-Tax Margin

            • -0.34

            • 13.77

            • Net Profit Margin

            • -0.16

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 67.80

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 8.30

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 8.60

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.26

              • 0.33

              • Current Ratio

              • 3.37

              • 1.52

              • Quick Ratio

              • 2.73

              • 0.87

              • Interest Coverage

              • 0.85

              • 6.77

              • Leverage Ratio

              • 2.03

              • 1.91

              • Book Value/Share

              • 13.98

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1,250.00

                • 65.36

                • P/E Ratio 5-Year High

                • -2,232.08

                • 237.47

                • P/E Ratio 5-Year Low

                • -368.77

                • 19.71

                • Price/Sales Ratio

                • 2.05

                • 3.63

                • Price/Book Value

                • 1.62

                • 3.39

                • Price/Cash Flow Ratio

                • 10.29

                • 21.83

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -0.15

                    (9.50)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -0.08

                    (6.80)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • 0.90

                    (8.40)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 3.41

                  • 1.80

                  • Asset Turnover

                  • 0.48

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  13.19M
                  Operating Margin
                  1.92
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  10.29
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  68.30%

                  Mutual Fund Ownership

                  70.54%

                  Float

                  73.53%

                  5% / Insider Ownership

                  1.77%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Health Care Fund

                  •  

                    4,700,058

                  • 0.00

                  • 7.22

                  • Royce Premier Fund

                  •  

                    3,777,388

                  • -2.05

                  • 5.80

                  • Fidelity® Value Fund

                  •  

                    1,700,568

                  • 0.00

                  • 2.61

                  • PowerShares Dynamic Pharmaceuticals Port

                  •  

                    1,600,904

                  • 0.00

                  • 2.42

                  • T. Rowe Price Health Sciences Fund

                  •  

                    1,329,200

                  • -49.89

                  • 2.04

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    1,309,276

                  • 0.57

                  • 1.97

                  • Fidelity® Select Health Care Portfolio

                  •  

                    1,150,000

                  • 0.00

                  • 1.77

                  • Vanguard Small Cap Index

                  •  

                    1,131,330

                  • -0.18

                  • 1.74

                  • SPDR® S&P Pharmaceuticals ETF

                  •  

                    1,051,755

                  • 0.00

                  • 1.58

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    9,029,419

                  • -0.16%

                  • 13.87

                  • Royce & Associates, LLC

                  •  

                    6,656,025

                  • +8.84%

                  • 10.22

                  • Fidelity Management and Research Company

                  •  

                    4,570,462

                  • +13.53%

                  • 7.02

                  • BlackRock Fund Advisors

                  •  

                    4,419,092

                  • -0.27%

                  • 6.79

                  • Vanguard Group, Inc.

                  •  

                    4,248,852

                  • -1.35%

                  • 6.52

                  • T. Rowe Price Associates, Inc.

                  •  

                    3,882,025

                  • -30.64%

                  • 5.96

                  • PointState Capital LP

                  •  

                    3,468,314

                  • +45.95%

                  • 5.33

                  • Putnam Investment Management,LLC

                  •  

                    2,556,861

                  • +474.65%

                  • 3.93

                  • State Street Corp

                  •  

                    2,333,314

                  • +3.28%

                  • 3.58

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Speculative Growth

                  Style

                  Small Core

                  The Medicines Company was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,00...more0 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax® (bivalirudin), Recothrom® Thrombin, topical (Recombinant), Cleviprex® (clevidipine) injectable emulsion and Minocin® IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections...more caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps™ and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA® (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.lessless

                  Key People

                  Dr. Clive A. Meanwell,M.D.

                  CEO/Chairman of the Board/Director

                  Glenn P. Sblendorio

                  CFO/Chief Accounting Officer/Director/Executive VP/President/Treasurer

                  Brent Furse

                  Executive VP/Other Executive Officer

                  Cornelis Heiman

                  Executive VP/Other Executive Officer

                  Victoria Kusiak

                  Executive VP/Other Executive Officer

                  • The Medicines Company

                  • 8 Sylvan Way

                  • Parsippany, NJ 07054

                  • USA.Map

                  • Phone: +1 973 290-6000

                  • Fax: +1 973 656-9898

                  • themedicinescompany.com

                  Incorporated

                  1996

                  Employees

                  571

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: